NJAAIS 2017 Teaching Day

Long Branch, NJ US
September 11, 2017

Didactic lectures allow the speakers to provide evidence based medical recommendations, updates and expert opinion in an efficient manner held in a one day meeting.

Target Audience

Practicing allergists, primary care physicians, advanced practice providers and allied healthcare providers in the field of allergy.

 

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the New Jersey Allergy, Asthma and Immunology Society (NJAAIS).  The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learning Objectives

1. Describe the role of the allergist/immunologist in diagnosing autoinflammatory disorders.

2. Identify differences in presentation and pathophysiology of common adult and pediatric autoinflammatory diseases.

3. Describe which environmental exposures are critical in the initiation and exacerbation of allergies and asthma.

4. Identify which evidence-based interventions are most effective and how to overcome socioeconomic and structural hurdles to implement these interventions in a practical way in our patients’ homes and community.

5. Recognize the latest updates on preventative guidelines for food allergy

6. Discuss safety and efficacy of food allergy therapies currently under investigation and explore the utility of combination therapies for food allergy.

7. Discuss the importance of asthma in older patients.

8. Recognize the effect of aging on inflammation and asthma.

9. Identify treatment approaches to asthma in older patients.

10. Discuss the new payment models and understand how other regulatory changes are impacting allergy practice.

11. List options to avoid Medicare penalties in 2019

12. Define an APM.

Additional information
Disclosure: 

Disclosure Policy and Disclosures

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

 

All identified conflicts of interest have been resolved.

 

▲Allen Meadows, MD

    Speaker: ACAAI, Meda, Mylan, Boehringer Ingelheim

Advisory Board: ACAAI

Consultant: Meda

Honorarium: Meda, Mylan

 

▲Julie Wang, MD

Speaker: Aimmune

Advisory Board: JDP Therapeutics

Consultant: Aimmune

Honorarium: Aimmune

Consultant Fee: Aimmune

Ownership Interest: JDP Therapeutics

Author: UpToDate

Royalty: UpToDate

 

▲ Lori Broderick, MD

None

 

▲Paula Busse, MD

Advisory Board: CSL Behring, Shire, Pharming, Pearl Therapeutics, Teva

Honorarium: CSL Behring, Shire, Pharming, Pearl Therapeutics, Teva

Research: CSL Behring, Shire, Pharming

 

▲Wanda Phipatanakul, MD

None

 

▲Satya Narisety, MD

None

Course summary
Available credit: 
  • 5.00 AMA PRA Category 1 Credit™
  • 5.00 Attendance
Course opens: 
09/11/2017
Course expires: 
09/11/2019
Event starts: 
09/11/2017 - 7:30am CDT
Event ends: 
09/11/2017 - 3:30pm CDT
Add to calendar: 
Rating: 
0
Ocean Place Hotel
1 Ocean Boulevard
Long Branch, NJ 07740
United States
+1 (800) 411-6493

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the New Jersey Allergy, Asthma and Immunology Society (NJAAIS).  The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 5.00 AMA PRA Category 1 Credit™
  • 5.00 Attendance
Please login or create an account to take this course.